260 related articles for article (PubMed ID: 18824712)
21. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
[TBL] [Abstract][Full Text] [Related]
22. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
da Fonseca CO; Schwartsmann G; Fischer J; Nagel J; Futuro D; Quirico-Santos T; Gattass CR
Surg Neurol; 2008 Sep; 70(3):259-66; discussion 266-7. PubMed ID: 18295834
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Gururangan S; Peters KB; McLendon R; Sathornsumetee S; Rich JN; Lipp ES; Janney D; Friedman HS
Cancer; 2012 Oct; 118(19):4759-67. PubMed ID: 22371319
[TBL] [Abstract][Full Text] [Related]
24. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Huang CH; Williamson SK; Van Veldhuizen PJ; Hsueh CT; Allen A; Tawfik O; Wick J; Smith H; Uypeckcuat AM; Mayo M; Kelly K
J Thorac Oncol; 2011 Feb; 6(2):372-7. PubMed ID: 21178640
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Odia Y; Iwamoto FM; Moustakas A; Fraum TJ; Salgado CA; Li A; Kreisl TN; Sul J; Butman JA; Fine HA
J Neurooncol; 2016 Mar; 127(1):127-35. PubMed ID: 26643807
[TBL] [Abstract][Full Text] [Related]
26. 3D conformal radiotherapy and cisplatin for recurrent malignant glioma.
VanderSpek L; Fisher B; Bauman G; Macdonald D
Can J Neurol Sci; 2008 Mar; 35(1):57-64. PubMed ID: 18380278
[TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
29. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
33. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
Alberts DS; Liu PY; Wilczynski SP; Jang A; Moon J; Ward JH; Beck JT; Clouser M; Markman M
Int J Gynecol Cancer; 2007; 17(4):784-8. PubMed ID: 17343607
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA
J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
Horak P; Wöhrer A; Hassler M; Hainfellner J; Preusser M; Marosi C
J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
